Enliven Therapeutics (ELVN) Capital Expenditures (2019 - 2025)
Enliven Therapeutics (ELVN) reported Capital Expenditures of -$1000.0 for Q3 2025, down 104.76% on a YoY basis from $21000.0 in Q3 2024, and down 100.72% sequentially from $139000.0 in Q2 2025.
Enliven Therapeutics (ELVN) Capital Expenditures (2019 - 2025) Analysis & Trends
Enliven Therapeutics (ELVN) has 7 years of Capital Expenditures data on file, last reported at -$1000.0 in Q3 2025.
- For the quarter ending Q3 2025, Capital Expenditures fell 104.76% year-over-year to -$1000.0; the trailing twelve-month figure through Mar 2026 stood at $138000.0 (up 213.64% YoY), and the FY2025 full-year result was $158000.0, up 259.09% from the prior year.
- Capital Expenditures slipped to -$1000.0 in Q3 2025, from $139000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $303000.0 in Q2 2022 to a low of -$1000.0 in Q3 2025.
- A 5-year average of $65000.0 and a median of $20000.0 in 2024 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 4533.33% in 2025, while the deepest fall reached 104.76% in 2025.
- Tracing ELVN's Capital Expenditures over 5 years: stood at $12000.0 in 2021, then jumped by 741.67% to $101000.0 in 2022, then tumbled by 86.14% to $14000.0 in 2023, then jumped by 50.0% to $21000.0 in 2024, then slumped by 104.76% to -$1000.0 in 2025.
- Business Quant data shows ELVN's Capital Expenditures at -$1000.0 in Q3 2025, $139000.0 in Q2 2025, and $20000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 786,000.00 |
| 10 | Enliven Therapeutics | 3.33 Bn | 2.88 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | 139,000.00 |
| Jun 30, 2025 | 139,000.00 |
| Mar 31, 2025 | 20,000.00 |
| Mar 31, 2025 | 20,000.00 |
| Sep 30, 2024 | 21,000.00 |
| Sep 30, 2024 | 21,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Sep 30, 2023 | 16,000.00 |
| Sep 30, 2023 | 16,000.00 |
| Jun 30, 2023 | 88,000.00 |
| Jun 30, 2023 | 88,000.00 |
| Mar 31, 2023 | 31,000.00 |
| Mar 31, 2023 | 31,000.00 |